Livingston, Scotland – 16 March 2015 – Touch Bionics, a provider of world-leading upper limb prosthetic technologies, today welcomed the news that its i-limb technology is now fully reimbursed in the French market, with the recent approval of the company’s LPPR Code application by the French Health Authorities.
The i-limb ultra is the first multi-articulating bionic hand to receive reimbursement approval in France, and today’s news is therefore an important development for the many patients who have been waiting to receive this standard of electronic prosthetic hand.
“We welcome the decision by the French Health Authorities to offer the most advanced technology available to upper limb prosthetic users,” said Ian Stevens, CEO, Touch Bionics. “Our comprehensive support and training programmes are designed to enable significant restoration of function to individuals following the trauma of upper limb loss.”
About Touch Bionics
Touch Bionics is a provider of world-leading prosthetic technologies designed to achieve positive outcomes for people with upper limb deficiencies. Touch Bionics was the first company to develop an electrically powered prosthetic hand with five independently powered fingers and the company continues to be a pioneer in upper limb prosthetic solutions. The company's products include electronic prosthetic hand and prosthetic finger solutions, as well as passive silicone prostheses that closely match the natural appearance of the wearer.
A spin-out of the UK's National Health Service, Touch Bionics was founded by inventor David Gow and is funded and supported by Archangel Investment and Scottish Enterprise.